Advertisement

Photon activation therapy: a Monte Carlo study on dose enhancement by various sources and activation media

  • Mahdi Bakhshabadi
  • Mahdi GhorbaniEmail author
  • Ali Soleimani Meigooni
Scientific Paper

Abstract

In the present study, a number of brachytherapy sources and activation media were simulated using MCNPX code and the results were analyzed based on the dose enhancement factor values. Furthermore, two new brachytherapy sources (131Cs and a hypothetical 170Tm) were evaluated for their application in photon activation therapy (PAT). 125I, 103Pd, 131Cs and hypothetical 170Tm brachytherapy sources were simulated in water and their dose rate constant and the radial dose functions were compared with previously published data. The sources were then simulated in a soft tissue phantom which was composed of Ag, I, Pt or Au as activation media uniformly distributed in the tumour volume. These simulations were performed using the MCNPX code, and dose enhancement factor (DEF) was obtained for 7, 18 and 30 mg/ml concentrations of the activation media. Each source, activation medium and concentration was evaluated separately in a separate simulation. The calculated dose rate constant and radial dose functions were in agreement with the published data for the aforementioned sources. The maximum DEF was found to be 5.58 for a combination of the 170Tm source with 30 mg/ml concentration of I. The DEFs for 131Cs and 170Tm sources for all the four activation media were higher than those for other sources and activation media. From this point of view, these two sources can be more useful in photon activation therapy with photon emitter sources. Furthermore, 131Cs and 170Tm brachytherapy sources can be proposed as new options for use in the field of PAT.

Keywords

Brachytherapy Photon activation therapy Dose enhancement TG-43 parameters 

Notes

Acknowledgments

The authors are thankful to Dr. Facundo Ballester for his help to review the manuscript. The authors would also like to thank North Khorasan University of Medical Sciences for funding this work.

References

  1. 1.
    Laster BH, Dixon DW, Novick S, Feldman JP, Seror V, Goldbart ZI et al (2009) Photon activation therapy and brachytherapy. Brachytherapy 8(3):324–330PubMedCrossRefGoogle Scholar
  2. 2.
    Young LA, Kalet IJ, Rasey JS, Nelson JA (1998) 125I brachytherapy k-edge dose enhancement with AgTPPS4. Med Phys 25(5):709–718PubMedCrossRefGoogle Scholar
  3. 3.
    Sastry KSR (1992) Biological effects of the Auger emitter iodine-125: a review. Report No. 1 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 19(6):1361–1370PubMedCrossRefGoogle Scholar
  4. 4.
    Corde S, Biston MC, Elleaume H, Estève F, Charvet AM, Joubert A et al (2002) Lack of cell death enhancement after irradiation with monochromatic synchrotron X-rays at the K-shell edge of platinum incorporated in living SQ20B human cells as cis-diamminedichloroplatinum (II). Radiat Res 158(6):763–770PubMedCrossRefGoogle Scholar
  5. 5.
    Ferrer S (2005) Radiation therapy with synchrotron radiation and cisplatin-based chemotherapy as a treatment of gliomas. Med Clin (Barc) 124(7):271–273CrossRefGoogle Scholar
  6. 6.
    Laster BH, Thomlinson WC, Fairchild RG (1993) Photon activation of iododeoxyuridine: biological efficacy of Auger electrons. Radiat Res 133(2):219–224PubMedCrossRefGoogle Scholar
  7. 7.
    Suortti P, Thomlinson W (2003) Medical applications of synchrotron radiation. Phys Med Biol 48(13):1–35CrossRefGoogle Scholar
  8. 8.
    Nath R, Bongiorni P, Rossi PI, Rockwell S (1990) Enhanced IUdR radiosensitization by 241Am photons relative to 226Ra and 125I photons at 0.72 Gy/h. Int J Radiat Oncol Biol Phys 18(6):1377–1385PubMedCrossRefGoogle Scholar
  9. 9.
    Ranjbar H, Shamsaei M, Ghasemi MR (2010) Investigation of the dose enhancement factor of high intensity low mono-energetic X-ray radiation with labeled tissues by gold nanoparticles. Nukleonika 55(3):307–312Google Scholar
  10. 10.
    Karnas SJ, Moiseenko VV, Yu E, Truong P, Battista JJ (2001) Monte Carlo simulations and measurement of DNA damage from X-ray-triggered auger cascades in iododeoxyuridine (IUdR). Radiat Environ Biophys 40(3):199–206PubMedCrossRefGoogle Scholar
  11. 11.
    Moiseenko VV, Karnas SJ, Yu E, Battista JJ (2002) Monte Carlo simulations of DNA damage from incorporated cold iodine following photoelectrically induced Auger electron cascades. Radiat Prot Dosimetry 99(1–4):113–116PubMedCrossRefGoogle Scholar
  12. 12.
    Stephens BJ (2010) 161Ho+IUdR: optimized photon activation therapy. Ph. D. Thesis in Physics, http://etd.library.vanderbilt.edu/available/etd-05122010-153611/unrestricted/Stephens_Bryan_dissertation.pdf, Accessed Sept 10, 2012, Vanderbilt University
  13. 13.
    Young LA, Phillips MH, Nelson JA (1999) Validation of K-edge 125I brachytherapy enhancement with silver compounds. Phys Med Biol 44(8):1921–1935PubMedCrossRefGoogle Scholar
  14. 14.
    Meigooni AS, Hayes JL, Zhang H, Sowards K (2002) Experimental and theoretical determination of dosimetric characteristics of IsoAid ADVANTAGE 125I brachytherapy source. Med Phys 29(9):2152–2158PubMedCrossRefGoogle Scholar
  15. 15.
    Meigooni AS, Dini SA, Awan SB, Dou K, Koona RA (2006) Theoretical and experimental determination of dosimetric characteristics for ADVANTAGE Pd-103 brachytherapy source. Appl Radiat Isot 64(8):881–887PubMedCrossRefGoogle Scholar
  16. 16.
    Murphy MK, Piper RK, Greenwood LR, Mitch MG, Lamperti PJ, Seltzer SM et al (2004) Evaluation of the new cesium-131 seed for use in low-energy X-ray brachytherapy. Med Phys 31(6):1529–1538PubMedCrossRefGoogle Scholar
  17. 17.
    Ballester F, Granero D, Perez-Calatayud J, Venselaar JL, Rivard MJ (2010) Study of encapsulated 170Tm sources for their potential use in brachytherapy. Med Phys 37(4):1629–1637PubMedCrossRefGoogle Scholar
  18. 18.
    http://www.physics.carleton.ca/clrp/seed_database/I125/Advantage_IA1-125A, Accessed September 10, 2012, Carleton University
  19. 19.
    http://www.physics.carleton.ca/clrp/seed_database/Pd103/Advantage_IAPd_103A, Accessed September 10, 2012, Carleton University
  20. 20.
    Granero D, Pérez-Calatayud J, Casal E, Ballester F, Venselaar J (2006) A dosimetric study on the Ir-192 high dose rate flexisource. Med Phys 33(12):4578–4582PubMedCrossRefGoogle Scholar
  21. 21.
    Young LA, Phillips MH, Nelson JA (1999) Validation of K-edge 125I brachytherapy enhancement with silver compounds. Phys Med Biol 44(8):1921–1935PubMedCrossRefGoogle Scholar
  22. 22.
    University of Washington. http://skuld.bmsc.washington.edu/scatter/AS_periodic.html, Accessed September 10, 2012
  23. 23.
    Rivard MJ, Coursey BM, DeWerd LA, Hanson WF et al (2004) Update of AAPM Task Group No. 43 Report: a revised AAPM protocol for brachytherapy dose calculations. Med Phys 31(3):633–674PubMedCrossRefGoogle Scholar
  24. 24.
    Bahreyni Toossi MT, Ghorbani M, Mowlavi AA, Soleimani Meigooni A (2012) Dosimetric characterizations of GZP6 60Co high dose rate brachytherapy sources: application of superimposition method. Radiol Oncol 46(2):170–178PubMedGoogle Scholar
  25. 25.
    Slate LJ, Elson HR, Lamba MA, Kassing WM, Soldano M, Barrett WL (2004) A Monte Carlo brachytherapy study for dose distribution prediction in an inhomogeneous medium. Med Dosim 29(4):271–278PubMedCrossRefGoogle Scholar
  26. 26.
    Mowlavi AA, Binesh A, Moslehitabar H (2006) Dose distribution and dosimetry parameters calculation of MED3633 palladium-103 source in water phantom using MCNP. Iran J Radiat Res 4(1):15–119Google Scholar
  27. 27.
    Waters LS, MCNPX User’s Manual, Version 2.4.0., Report LA-CP-02-408 2000, Los Alamos National LaboratoryGoogle Scholar
  28. 28.
  29. 29.
    Rivard MJ (2001) A discretized approach to determining TG-43 brachytherapy dosimetry parameters: case study using Monte Carlo calculations for the MED3633 103Pd source. Appl Radiat Isot 55(6):775–782PubMedCrossRefGoogle Scholar
  30. 30.
    Rivard MJ (2007) Brachytherapy dosimetry parameters calculated for a 131Cs source. Med Phys 34(2):754–762PubMedCrossRefGoogle Scholar
  31. 31.
    ICRU (1989) Tissue substitutes in radiation dosimetry and measurement. ICRU Report no. 44. International Commission on Radiation Units and Measurements, Bethesda, MDGoogle Scholar
  32. 32.
    Sowards KT (2007) Monte Carlo dosimetric characterization of the IsoAid ADVANTAGE 103Pd brachytherapy source. J Appl Clin Med Phys 8(2):18–25PubMedGoogle Scholar

Copyright information

© Australasian College of Physical Scientists and Engineers in Medicine 2013

Authors and Affiliations

  • Mahdi Bakhshabadi
    • 1
  • Mahdi Ghorbani
    • 2
    Email author
  • Ali Soleimani Meigooni
    • 3
  1. 1.North Khorasan University of Medical SciencesBojnurdIran
  2. 2.Medical Physics Department, Faculty of MedicineMashhad University of Medical SciencesMashhadIran
  3. 3.Comprehensive Cancer Centers of NevadaLas VegasUSA

Personalised recommendations